Thus, the patients can be treated in advance with appropriate medication. The long-term goal is to release these drugs directly in the affected brain region. This is to happen via living cells coated electrodes in which the active ingredient is produced directly. The meter will be powered by a 5-cc battery and will be tested on patients for the first time in two years.
The smallest possible low-power meter was also the development goal of Purdue University's second working group, which is working on an implantable probe to determine intraocular pressure. The device is implanted between two tissue layers in the eye and also sends its measurement data to an external receiver. Thus, the intraocular pressure, which is considered a major risk factor for glaucoma, constantly monitored.
Although such a measurement can also be made externally by the ophthalmologist, explains Irazoqui. The difficulty, however, is that the intraocular pressure changes within hours, sometimes minutes and so a single short measurement does not give a coherent picture. First, the device is tested in animal experiments. The first tests with patients should then follow in about one and a half years. displayCommunication from Purdue University, West Lafayette ddp / science.de? Ulrich Dewald